Five-year Results of the Phase III Intergroup Trial (RTOG 97-04) of Adjuvant Pre- and Postchemoradiation (CRT) 5-FU vs. Gemcitabine (G) For Resected Pancreatic Adenocarcinoma: Implications for Future International Trial Design

Reviewer: Charles B. Simone, II, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 9 de noviembre del 2009

Translation for this article does not exist